Frataxin mRNA in Biofluids
- Conditions
- Friedreich Ataxia
- Interventions
- Other: Spinal tap for CSF collectionOther: Venipuncture for blood sample
- Registration Number
- NCT06496451
- Lead Sponsor
- University of Florida
- Brief Summary
The purpose of this research study is to determine a way to measure frataxin messenger RNA (mRNA) in fluids such as blood and cerebrospinal fluid (CSF) from patients with Friedreich's ataxia (FRDA). The gene mutation in FRDA leads to low levels of the mRNA and then low levels of the protein frataxin that leads to the disease. Treatments being developed for FRDA have the ability increase these levels including in brain where it is needed. Currently, there is no accepted way to measure frataxin protein or the messenger RNA (from which the protein is made) in the spinal fluid that surrounds the brain. In our study, we aim to measure frataxin mRNA in both the blood and CSF. We will use our ability to isolate structures called exosomes from these fluids. Exosomes are tiny, microscopic sacs that are known to contain many important biological molecules and we are able to detect frataxin mRNA in CSF from patients with other illnesses and from non-diseased participants. We believe that parallel studies of exosomes in blood and CSF from patients with FRDA can tell us as to whether the frataxin mRNA in the CSF or blood of FRDA patients can serve as a measure of frataxin production in the brain. With one participation visit we will be able to study the relationship of frataxin mRNA levels in your CSF and blood with measures of disease severity. If successful, this will provide an important tool to monitor treatments for FRDA that aim to increase frataxin production.
- Detailed Description
Overview of the Study Participants will complete the study during 2 visits (visit 1 and 2). Visit 1 can be combined with a routine clinic visit for care or research but also may be done remotely via Zoom. During visit 1, the investigators will fully explain the study and obtain your informed consent. For remote visits, a copy of the consent will be emailed to you before the visit and the study team will schedule a time to discuss the consent. The informed consent will be reviewed in detail with you and you will have an opportunity to ask any questions before signing the document and agreeing to the study. In either case, once you agree to the study after being fully informed, you will sign the consent document and a copy of it will be provided to you after the investigator signs it.
Once informed consent has been obtained, you will be asked to obtain lab work to test your blood for its ability to clot well. This lab work will be reviewed before visit 2. Visit 2 will take several hours (less than 6 to 8 hours) and will involve collection of clinical data, collection of a blood sample and then collection of spinal fluid.
Description of Study Procedures
Blood Work prior to scheduled visit (\~30 minutes)
• You will need to go to one of the University of Florida Health's (UF Health's) local labs in Gainesville, Florida (FL) to have blood work done before the scheduled visit. This blood work will ensure you meet the inclusion criteria before the spinal tap.
Overall health and safety assessment (\~30 minutes)
* Your birthdate, gender, contact information, health history, current medications, and allergies will be obtained. The information will be stored in your study file.
* If you are a woman of childbearing potential, your urine sample will be tested to see if you are pregnant. If the test is positive, you will not be able to continue in the study.
* Your FRDA DNA test from your medical record will be assessed and a copy placed in the research folder. No additional genetic testing will be performed.
* Measurements such as your height, weight, blood pressure, pulse, respiratory rate, and temperature will be obtained.
* A general physical examination will be done by the study physician
Neurological examination, modified Friedreich Ataxia Rating Scale (mFARS), and blood sample (\~30 minutes)
* The study physician will perform a neurological examination and use this to rate your ataxia severity in the mFARS scale.
* This will include examining your eye movements, speech, strength of your muscles, sensation, coordination in your arms and legs and ability to stand and walk among other things.
* We will ask you questions regarding your activities of daily living for a questionnaire called FRDA activities of daily living scale (FARS ADL).
* A blood sample of approximately 5-10 milliliters (or 1-2 teaspoonfuls) will be obtained.
Spinal Tap (\~3 hours)
* About 15 milliliters or 1 tablespoon of cerebrospinal fluid (CSF) will be collected though a test called a spinal tap.
* The spinal tap will be performed in the interventional radiology suite at the Neuromuscular hospital via x-ray fluoroscopy.
* This procedure uses X-ray (fluoroscopy) to visualize your low back spine so that the spinal tap needle can be placed in the spinal sac in your low back under visual guidance. This can minimize discomfort and can help increase the success of the procedure in one attempt.
* You will be given local anesthesia to numb the area before collection.
* You will be asked to relax while laying down following the procedure for 1 to 2 hours before leaving.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 10
- Patients with symptomatic Friedreich ataxia (men and women) related to documented biallelic GAA expansion in the FXN gene
- Age over 18 years
- No contraindication to spinal tap including any coagulopathy or local infections
- Competent to provide informed consent
- Unable or unwilling to provide informed consent
- Any uncontrolled medical illness that may increase the risk of spinal tap such as ongoing infection as determined by the investigators
- FRDA related to an expansion in one allele and a conventional mutation on the other
- Positive pregnancy screening
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Friedreich ataxia Spinal tap for CSF collection Adult patients with genetically proven Friedreich ataxia Friedreich ataxia Venipuncture for blood sample Adult patients with genetically proven Friedreich ataxia
- Primary Outcome Measures
Name Time Method Measurement of Frataxin mRNA in human biofluids One year The study plans to measure frataxin mRNA in exosomes from blood and spinal fluid as a biomarker in Friedreich ataxia
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Florida
🇺🇸Gainesville, Florida, United States